ARMP

Armata is a late clinical-stage bacteriophage developer with zero product revenue across its entire reported history (FY2021–FY2025), so the equity is worth only what the AP-PA02 and AP-SA02 pipelines eventually produce. The MD&A confirms the state of play: three completed Phase 2 trials and 'positive topline' SWARM-P.a. data, but nothing approved, nothing generating cash, and cGMP manufacturing space that was only occupied in late 2024. Every dollar of value here is a bet on unproven clinical readouts, not on a business.

The balance sheet is the disqualifier. Cash and equivalents are just $8.69M against operating cash burn of -$25.8M per year — under five months of runway on the face of it — while total liabilities jumped 119.8% to $295M and stockholders' equity swung to -$219M (a -1.35x liabilities/equity ratio). Retained-earnings deficit is -$502M. The FY2025 net loss of -$174M dwarfs the -$36.6M operating loss, so roughly $137M is non-operating — almost certainly a non-cash revaluation (warrant/derivative or similar) that is also what inflated liabilities and drove equity deeply negative. Either way, current assets of $10.7M cannot service a $295M liability base, and the company is already 'actively seeking a sub-tenant' to shed its Marina del Rey lease — a cost-cutting tell.